GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVie Inc (NAS:BIVI) » Definitions » Cyclically Adjusted PB Ratio

BIVI (BioVie) Cyclically Adjusted PB Ratio : 0.17 (As of May. 27, 2025)


View and export this data going back to 2014. Start your Free Trial

What is BioVie Cyclically Adjusted PB Ratio?

As of today (2025-05-27), BioVie's current share price is $1.05. BioVie's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $6.04. BioVie's Cyclically Adjusted PB Ratio for today is 0.17.

The historical rank and industry rank for BioVie's Cyclically Adjusted PB Ratio or its related term are showing as below:

BIVI' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.17
Current: 0.17

During the past years, BioVie's highest Cyclically Adjusted PB Ratio was 0.17. The lowest was 0.00. And the median was 0.00.

BIVI's Cyclically Adjusted PB Ratio is ranked better than
83.41% of 669 companies
in the Biotechnology industry
Industry Median: 1.48 vs BIVI: 0.17

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BioVie's adjusted book value per share data for the three months ended in Mar. 2025 was $1.178. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $6.04 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


BioVie Cyclically Adjusted PB Ratio Historical Data

The historical data trend for BioVie's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVie Cyclically Adjusted PB Ratio Chart

BioVie Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 7.03 0.68

BioVie Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 0.68 0.20 0.34 0.16

Competitive Comparison of BioVie's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, BioVie's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVie's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVie's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BioVie's Cyclically Adjusted PB Ratio falls into.


;
;

BioVie Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

BioVie's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.05/6.04
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVie's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, BioVie's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.178/134.9266*134.9266
=1.178

Current CPI (Mar. 2025) = 134.9266.

BioVie Quarterly Data

Book Value per Share CPI Adj_Book
201506 -0.771 100.684 -1.033
201509 -1.529 100.392 -2.055
201512 -2.214 99.792 -2.993
201603 -3.014 100.470 -4.048
201606 27.371 101.688 36.318
201609 22.543 101.861 29.861
201612 18.957 101.863 25.110
201703 20.178 102.862 26.468
201706 15.635 103.349 20.412
201709 14.237 104.136 18.447
201712 10.408 104.011 13.502
201803 7.115 105.290 9.118
201806 1.405 106.317 1.783
201809 15.972 106.507 20.234
201812 14.052 105.998 17.887
201903 11.008 107.251 13.849
201906 5.249 108.070 6.553
201909 -16.836 108.329 -20.970
201912 -3.946 108.420 -4.911
202003 -4.508 108.902 -5.585
202006 -41.344 108.767 -51.288
202009 10.486 109.815 12.884
202012 9.393 109.897 11.532
202103 8.168 111.754 9.862
202106 2.262 114.631 2.662
202109 8.107 115.734 9.451
202112 6.431 117.630 7.377
202203 3.985 121.301 4.433
202206 1.470 125.017 1.587
202209 1.976 125.227 2.129
202212 7.556 125.222 8.142
202303 6.011 127.348 6.369
202306 4.211 128.729 4.414
202309 2.046 129.860 2.126
202312 1.880 129.419 1.960
202403 3.104 131.776 3.178
202406 2.505 132.554 2.550
202409 1.768 133.029 1.793
202412 1.296 133.157 1.313
202503 1.178 134.927 1.178

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioVie  (NAS:BIVI) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


BioVie Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of BioVie's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVie Business Description

Industry
Traded in Other Exchanges
N/A
Address
680 W Nye Lane, Suite 204, Carson, NV, USA, 89703
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Executives
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Cuong V Do director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
James Paul Lang director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Michael Edward Sherman director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Robert J Hariri director 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Joanne Wendy Kim officer: Chief Financial Officer C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Joseph M Palumbo other: Chief Medical Officer 616 BROOKSIDE AVENUE, SAINT DAVIDS PA 19087
Jonathan M Adams officer: EVP Liver Cirrhosis Programs 100 CUMMINGS CENTER 247C, BEVERLY MA 01915
Penelope Markham officer: EVP Liver Cirrhosis R&D C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Christopher Reading officer: EVP Neuroscience R&D C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Clarence N. Ahlem officer: EVP of Product Development 5305 RENAISSANCE AVE., SAN DIEGO CA 92122
Mina Sooch director 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Sigmund Rogich director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Patrick D Yeramian officer: Chief Medical Officer 1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486

BioVie Headlines